Organisation paid for research Program year 2022 Source: CMS Open Payments

OHSU Hospital

Neither a doctor nor a teaching hospital

Research payments

$438,967

256 payments

Through program year 2022, OHSU Hospital is reported as receiving $438,967 in research payments, across 256 payments.

By program year

3 rows
Year Kind Amount Payments
2022 Research $143,083 244
2021 Research $85 1
2020 Research $295,799 11

Breakdown

Who paid Research payments · program years 2020–2022
  1. Celgene Corporation $277,982 5 payments
  2. Eisai Inc. $143,083 244 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $16,212 4 payments
  4. Novartis Pharmaceuticals Corporation $1,691 3 payments
Studies the money was for Research payments · program years 2020–2022
  1. (CC-99712-MM-001) Ph I R/R MM Dose Escalation (BMS Study Number: CA060-P01) $241,374 1 payment
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $72,148 35 payments
  3. A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors $70,935 209 payments
  4. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) $20,290 1 payment
  5. BAY2757556 dose escalation $16,212 4 payments
  6. Phase III Study - PANC-003 (BMS Study Number: CA139-P15) $9,140 1 payment
  7. Ph III Yellowstone CD OLE (RPC01-3204) (BMS Study Number: IM047-P17) $6,716 1 payment
  8. A Randomized, Double-Blind, Placebo-Controlled Phase II Multi-Center Study of Intravenous Mbg453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High Or Very High Risk Myelodysplastic Syndrome (MDS) As Per Ipss-R Criteria (Stimulus-MD $1,080 1 payment
  9. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $556 1 payment
  10. Ph III Yellowstone CD Maintenance (RPC01-3203) (BMS Study Number: IM047-P16) $462 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record